Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Pliant Therapeutics, Inc.
Eli Lilly and Company
M.D. Anderson Cancer Center
Kestrel Therapeutics, Inc.
Novartis
Hutchmed
Arbele Limited
City of Hope Medical Center
M.D. Anderson Cancer Center
Imugene Limited
M.D. Anderson Cancer Center
Myeloid Therapeutics
Servier
Jonsson Comprehensive Cancer Center
Massachusetts General Hospital
Seagen Inc.
Mayo Clinic
University of Maryland, Baltimore
University of Southern California
West China Hospital
Incyte Corporation
Mayo Clinic
Actym Therapeutics, Inc.
MacroGenics
Elicio Therapeutics
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
Leap Therapeutics, Inc.
Toray Industries, Inc
University Hospital, Ghent
NextPoint Therapeutics, Inc.
Eli Lilly and Company
Celldex Therapeutics
Kinnate Biopharma
Toray Industries, Inc
Boehringer Ingelheim
Zymeworks BC Inc.
Symphogen A/S
ABM Therapeutics Shanghai Company Limited
NGM Biopharmaceuticals, Inc
Tyra Biosciences, Inc
University of California, San Diego
Chang Gung Memorial Hospital
Symphogen A/S
ABM Therapeutics Corporation
Academic and Community Cancer Research United
NGM Biopharmaceuticals, Inc